Biotech Startups

ESIM Chemicals manufactures exclusive synthesis products and chemical intermediates for the pharmaceutical and specialty chemicals industries. The company has a long operational history in Austria, with roots in nitrogen fertilizer production that evolved into fine chemicals and pharmaceutical intermediates.

1 investor

Esperance develops targeted oncology therapeutics designed to selectively kill cancer cells, including chemotherapy-resistant cells, via a proprietary Cationic Lytic Peptide (CLYP) platform, membrane-disrupting peptides, and antibody drug conjugates. The company operates from Houston, Texas near the Texas Medical Center, with MD Anderson Cancer Center as a strategic partner.

1 investor

Essential Pharma develops and delivers pharmaceutical medicines for patients in niche populations, with a focus on rare disease, CNS, ophthalmology, and gastroenterology across approximately 70 countries.

1 investor

A diagnostics company developing in vitro diagnostic solutions, with an immunoassay platform built on Test-On-a-Probe biosensor technology. The company is headquartered in Silicon Valley and serves the medical/clinical diagnostics market.

1 investor

Etcembly builds EMLy Co-pilot, an AI platform with a conversational interface that unifies biologics design workflows—including structural modeling, variant generation, and molecule optimization—into a single tool. It serves biotechs and R&D organizations working on therapeutic candidates such as antibodies (mAbs) and TCRs.

1 investor

Eterna Regeneratives develops biomimetic materials that guide new mineral growth to repair lost tooth enamel using the body's own chemistry, with a patented platform extending to bone and wider tissue repair. Its work includes keratin-derived approaches, such as material extracted from hair and wool, aimed at enamel regeneration.

1 investor

Eternygen is a Berlin-based pharmaceutical company founded in 2012 that researches and develops drugs for diet-related metabolic diseases such as fatty liver, diabetes, and obesity. Its work centers on the sodium-coupled citrate transporter NaCT as a therapeutic target to correct the underlying metabolic defect.

1 investor

Ethypharm is a specialty pharmaceutical company that develops and provides injectable medicines focused on Central Nervous System conditions including severe pain and addiction treatment, as well as critical care hospital injectables. The company serves patients and healthcare providers in hospital and emergency care settings.

1 investor

Etiome develops stage-specific medicines by applying single-cell omics and artificial intelligence to map disease progression and identify disease-modifying targets at early biological inflection points for preemptive intervention. Founded in 2021 out of Flagship Pioneering's Preemptive Health and Medicine initiative, the biotech company focuses on treating or reversing disease before it advances to later stages.

1 investor

1 investor

Tissue Targeting Therapies develops therapeutics targeting specific tissues using computational genomics and immunology. The company serves patients through drug development in the biotech/medtech space.

1 investor

Eurofins Viracor is a clinical laboratory that develops and delivers diagnostic tests for infectious diseases, cellular function disorders, oncology, and transplant rejection monitoring. The company serves healthcare providers and patients in the United States through comprehensive laboratory services and biomarker research.

1 investor

Archimica is a contract manufacturer of active pharmaceutical ingredients (APIs), GMP building blocks and reagents, offering process development and production from clinical to large commercial scale for innovative and generic pharmaceutical companies. Operating from its Lodi site in Italy, it specializes in hazardous and difficult chemistry including anticancer APIs, and supplies customers across roughly 50 countries.

1 investor

Evaheart develops implantable and extracorporeal ventricular assist devices for heart failure and vascular disease treatment. The company manufactures medical devices and operates an integrated ecosystem including research, production, and clinical solutions.

1 investor

Evec (株式会社イーベック) is a Japanese biotechnology company that develops fully human monoclonal antibodies through its research labs. The page is a corporate officers/executive profile page listing the company's board members and auditors.

1 investor

Everest Biolabs develops automated instruments, size-exclusion chromatography columns, and ELISA assays for extracellular vesicle (EV) isolation, concentration, and quantification. Its tools serve research laboratories working on EV science.

1 investor

Evergreen Theragnostics manufactures radiopharmaceutical therapeutics and diagnostics for cancer treatment and develops novel radiotherapeutic agents for cancer patients. The company offers high-quality manufacturing services and handles product registration and commercialization for partner companies.

1 investor

1 investor

EVerMed is a company focused on extracellular vesicle biology and pharmaceutical development, combining academic expertise with industry experience in drug development and regenerative medicine.

1 investor

EVERSANA is an independent provider of integrated commercial services to the life sciences industry, supporting products across all stages of their life cycle. It serves over 670 organizations, including startups and established pharmaceutical companies, addressing the needs of patients, prescribers, channel partners and payers.

1 investor

eversyn produces human milk oligosaccharides and nucleotide sugars using proprietary cell-free biocatalytic technology for food and nutrition applications. The company emerged from the Max Planck Institute Magdeburg as a spin-out translating enzyme and bioprocess research into commercial production.

1 investor

EVerZom develops exosome formulation technologies that modify cells to release exosomes with enhanced therapeutic properties, designed for targeted delivery to specific tissue sites. The company creates formulated exosome drugs for treating pathologies through local or systemic administration routes.

1 investor

Evestia Clinical is a clinical research organization providing clinical trial services for biotech companies across oncology, rare disease, neurology, immunology, and inflammation. The company was established in 1996 and recently rebranded to reflect its expanded focus as a global clinical research provider.

1 investor

A company that developed a proprietary platform for single-cell immune profiling from small plasma volumes to enable non-invasive diagnostics. Founded from University of Zurich research, it applies immunology and data science to clinical diagnostics.

1 investor